linjc16/ctgov huggingface dataset:
Tap Water Intake and Perceptions in US Latinx Adults

Study Overview
=================
Brief Summary
-----------------
The purpose of this exploratory cross-sectional investigation is to evaluate associations between tap water perceptions, water consumption behaviors, and hydration status in Latinx adults (18 - 65 y). The objective is to identify perceptual determinants that explain the associations between tap water avoidance and plain water intake and hydration status in Latinx adults. Aim 1: Characterize the degree to which individual- and community-level factors uniquely predict the perception that tap water is not safe in Latinx adults. Aim 2: Evaluate household income, education level, and US nativity as potential moderators of the associations between predictors and perceptions of tap water safety. Aim 3: Evaluate the influence of tap water safety perceptions on plain water intake and 24-h hydration status, after adjustment for predictors of tap water safety perceptions, in a sub-sample of Latinx adults.

Official Title
-----------------
Tap Water Intake and Perceptions in US Latinx Adults

Conditions
-----------------
Dehydration

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Self-identify as Hispanic or Latinx English- and/or Spanish-speaking Interested in participating in both study phases Live in Phoenix, Arizona Exclusion Criteria: Currently pregnant or breastfeeding Currently use diuretics Do not have access to a desktop, laptop, tablet, or smartphone Do not have internet access

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Latinx Adults 18 - 65 y<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perception of tap water safety | This will be measured via the question What is your level of agreement with the following statement: My tap water is safe to drink. Possible responses include strongly disagree, disagree, agree, or strongly agree. | 1 day | 
| Plain water intake (mL) |  | 3-day average | 
| 24-h urine osmolality (mmol/kg) |  | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 24-h urine volume (mL) |  | 1 day | 
| Total water intake (mL) |  | 3-day average |
Molecular Markers in Treatment in Endometrial Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this prospective multicenter trial is to investigate the value of molecular markers in endometrial cancer for predicting lymph node metastasis and prognosis in relation to treatment.

Detailed Description
-----------------
This is a prospective multicenter study to investigate the predictive value of molecular markers in endometrial cancer for lymph node metastasis, prognosis and treatment. For the previously studied tumor markers p53, p16, ER, PR and HER2neu, we want to investigate the expression in curettage material in relation to lymph node metastasis and prognosis among endometrial carcinoma patients. We also want to investigate the distribution of genetic alterations in fresh frozen tumor tissue in order to design prospective randomized treatment trials of metastatic endometrial cancer based on molecular profile. There will be a special emphasis on disturbances in the pathways influenced by new targeted therapy, such as inhibitors of Her2/NEU, EGFR, receptor tyrosine kinase, mTOR, PTEN and hormone receptor pathways.

Official Title
-----------------
Prospective Study of Endometrial Cancer Treatment in Relation to Molecular Markers in Curettage Specimens.

Conditions
-----------------
Endometrial Neoplasms, Neoplasm Metastasis

Intervention / Treatment
-----------------
* Procedure: Tumor biopsy study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with endometrial carcinoma Available endometrial biopsy Informed consent Exclusion Criteria: No informed consent
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Consecutive numbers<br>Patients with endometrial cancer | Procedure: Tumor biopsy study<br>* Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of lymph node metastases |  | At primary treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrent disease, death from disease |  | 5 years after primary treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endometrial cancer, Molecular markers, Lymph node metastasis, Prospective study, Prognosis, Cancer of Endometrium, Tumor Markers, Biological
Hydroxychloroquine in COVID-19 Patients

Study Overview
=================
Brief Summary
-----------------
Many reports argued about the possible beneficial effects of Hydroxychloroquine in treating COVID-19 patients and this study was designed to investigate this claim

Official Title
-----------------
Use of Hydroxychloroquine in Patients With COVID-19: A Randomized Controlled Clinical Trial

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Drug: Hydroxychloroquine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed cases of SARS-CoV-2 by PCR Exclusion Criteria: less than 18 years old known hypersensitivity to the drug

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Hydroxycholoroquine group<br> | Drug: Hydroxychloroquine<br>* 400mg BD first day then 200 mg BD for 5 days<br>|
| No Intervention: Control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to viral clearance | PCR will be done every 72 h day till 2 consecutive negative PCR tests(24h apart) which is the viral clearance.The time between randomization and viral clearance is the viral clearance time | 21 days after patients randomization | 
| % of mortality | total number of deaths divided by total number of the group | 60 days after randomization | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of stay | time from patients randomization till discharge | 60 days after randomization | 
| time to be afebrile | time from randomization till day of fever subsiding | 60 days after randomization | 
| need for mechanical ventilation | %of deteriorated patients necessitates mechanical ventilation | 60 days after randomization |
The Impact of Patient Safety Incidents on Patients' Quality of Life

Study Overview
=================
Brief Summary
-----------------
This study estimates the impact of patient safety events on QoL in elective surgery patients using a secondary data set

Detailed Description
-----------------
Background: The burden of patient safety incidents (PSIs) is often characterised by their impact on mortality, morbidity and treatment costs. Few studies have attempted to estimate the impact of PSIs on patients' health-related quality of life (HRQoL) and the studies that have made such estimates primarily focus on a narrow set of incidents. The aim of this paper is to estimate the impact of PSIs on HRQoL of patients undergoing elective surgery in England. Materials and Methods: A unique linked longitudinal data set consisting of Patient Reported Outcome Measures (PROMS) for patients with hip and knee replacements linked to Hospital Episode Statistics (HES) collected between 2013/14 and 2016/17 is examined. Patients with any of nine US Agency for Healthcare Research and Quality (AHRQ) PSI indicators are identified. HRQoL is measured using the general EuroQol five dimensions questionnaire (EQ-5D) before and after surgery. Exploiting the longitudinal structure of the data, exact matching combined with difference in differences to estimate the impact of experiencing a PSI on HRQoL and its individual dimensions, comparing HRQoL improvements after surgery in similar patients with and without a PSI.

Official Title
-----------------
The Impact of Patient Safety Incidents on Patients' Quality of Life

Conditions
-----------------
Hip Fractures, Knee Fracture

Intervention / Treatment
-----------------
* Procedure: Surgery for hip and knee replacement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: no Exclusion Criteria: Patients for which health related quality of life is not observed both before and after surgery.
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients experiencing adverse event while in hospital<br>Patients that have experienced a patient safety incident according to the Patient Safety Indicators (PSIs) developed by the U.S. Agency for Healthcare Research and Quality (AHRQ) | Procedure: Surgery for hip and knee replacement<br>* Elective inpatient surgery for hip and knee replacement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EuroQual - 5 Dimensions (EQ5D) | quality of life | 2013-17 |
Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare 2nd line XELIRI/FOLFIRI + simvastatin vs XELIRI/FOLFIRI + placebo.

Detailed Description
-----------------
To compare progression free survival of the standard second line chemotherapy (FOLFIRI, XELIRI) plus simvastatin in metastatic colorectal cancer patients. This trial is a placebo-controlled study.

Official Title
-----------------
Placebo-controlled, Double-blinded Phase III Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Drug: Simvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically documented colorectal adenocarcinoma (previously failed to oxaliplatin) Age over 19 years old Performance status (ECOG scale): 0-2 Measurable or evaluable disease Adequate organ functions Life expectancy ≥ 3 months No history of statin treatment within the last 12 months Patients should sign a written informed consent before study entry. Exclusion Criteria: Tumor type other than adenocarcinoma Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin, papillary thyroid carcinoma or prior malignancy treated more than 5 years ago without recurrence) Adjuvant or neo-adjuvant treatment for non-metastatic (M0) disease is allowed if completed at least 6 months prior to initiation of study treatment. Prior radiotherapy is permitted if it was not administered to target lesions selected for this study, unless progression of the selected target lesions within the radiation portal is documented, and provided it has been completed at least 4 weeks before randomization.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: FOLFIRI or XELIRI/simvastatin<br>FOLFIRI or XELIRI/simvastatin | Drug: Simvastatin<br>* simvastatin 40 mg qd daily until disease progression<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colorectal cancer, simvastatin, second-line chemotherapy
PET FDG Assessment of Change in Atherosclerotic Plaques After Chemotherapy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether chemotherapy induces regression in atherosclerotic plaques in oncologic patients already undergoing PET FDG as part of their routine assessment.We will use PET FDG to assess whether the inflammation in atherosclerotic plaques is affected by chemotherapy and anti angiogenic therapy.

Conditions
-----------------
Atherosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women over the age of 65 diagnosed with metastatic breast cancer Men over the age of 65 diagnosed with lung cancer Exclusion Criteria: Patients under the age of 65 Patients diagnosed with chronic inflammatory disease or chronic infection Patients taking steroids and NSAIDS on a regular basis

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Breast cancer patients<br> | |
| Lung cancer patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Post-Market Observational Study of the WINX Sleep Therapy for the Treatment of Obstructive Sleep Apnea (OSA)

Study Overview
=================
Brief Summary
-----------------
The objective of the Study is to observe the use and utility of the Winx Sleep Therapy System in a clinical practice, for the treatment of patients with obstructive sleep apnea (OSA).

Official Title
-----------------
The UNMASK Study: A Post-Market Longitudinal Observational Study of the WinxTM Sleep Therapy System for the Treatment of Obstructive Sleep Apnea (OSA)

Conditions
-----------------
Obstructive Sleep Apnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Exclusion Criteria Has a severe respiratory disorder, such as severe lung disease, pneumothorax, etc. Has loose teeth or advanced periodontal disease. Is under the age of 18.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Winx<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Rickettsial Genesis to Sarcoidosis in Denmark

Study Overview
=================
Brief Summary
-----------------
One study has suggested a connection between an infection with Rickettsia species and sarcoidosis finding molecular evidence of rickettsial deoxyribonucleic acid (DNA) in two patients. Another study found no antibodies in twenty Swedish patients with sarcoidosis. This study will further enhance the subject by three different approaches in Danish patients. The purpose of this study is to find serological and molecular evidence of an infection with Rickettsia species in Danish patients with sarcoidosis.

Detailed Description
-----------------
The study has three approaches to the subject: A serological survey of rickettsial immunoglobin G (IgG)-antibodies in 50 patients with sarcoidosis compared to 50 blood donors without sarcoidosis. An archival study using pre-existing lymph node biopsies, where immunohistochemical analysis, fluorescent in situ hybridization, and polymerase chain reaction will be applied to samples from 50 patients with sarcoidosis and compared to 50 patients without sarcoidosis and 10 patients with tuberculosis. A prospective study using bronchoscopically obtained samples from 20 patients with sarcoidosis, compared to 20 patients without sarcoidosis. The study applies the same techniques as the second study, but enhancing the information from the patients.

Official Title
-----------------
Rickettsial Genesis to Sarcoidosis in Denmark

Conditions
-----------------
Sarcoidosis, Rickettsia Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Referred to fiberoptic bronchoscopy in the department either because of sarcoidosis, hemoptysis, chronic cough, or cancer suspicion Exclusion Criteria: Pregnant patients Patients under the age of 18 Patients without consent Patients with a registered wish of not having their samples used for research

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Controls<br>Patients without sarcoidosis, but requiring a fiberoptic bronchoscopy | |
| Sarcoidosis patients<br>Patients with newly diagnosed sarcoidosis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sarcoidosis, Rickettsia, Serological reactions, Polymerase chain reaction
Different Preoxygenation Methods In Cesarean Section

Study Overview
=================
Brief Summary
-----------------
The study aimed to evaluate different preoxygenation methods (tidal volume for 3 minutes and 4 deep breaths) in pregnant women with oxygen reserve index (ORI). After the routine monitoring of healthy ASA II pregnant patients between the ages of 18-45, different preoxygenation methods will be applied, and the oxygen status of the patients will be compared with ORI monitoring.

Official Title
-----------------
Assessment of Different Preoxygenation Methods With Oxygen Reserve Index In Cesarean Section

Conditions
-----------------
Hypoxia, Hyperoxia

Intervention / Treatment
-----------------
* Device: Oxygen Reserve Index


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The average operation time is 30 minutes-1.5 hours. ASA II risk class All pregnant women with a gestational week >36 Exclusion Criteria: preeclampsia eclampsia fetal distress morbid obesity a history of malignant hyperthermia opioid sensitivity alcohol or drug addiction congestive heart failure chronic obstructive pulmonary disease coronary artery disease anemia, liver and kidney disease hypovolemia, hypotension, sepsis Those who are allergic to the drugs used in the study and who are suspected of difficult intubation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group I<br>Preoxygenation with 100% oxygen for 3 minutes | Device: Oxygen Reserve Index<br>* It is a new non-invasive and continuous measurement parameter that aims to provide information about the oxygen status of patients in the moderately hyperoxic range (100 mmHg< PaO2 ≤ 200 mmHg).<br>|
| Group II<br>4 deep breaths with 100% oxygen in 30 seconds | Device: Oxygen Reserve Index<br>* It is a new non-invasive and continuous measurement parameter that aims to provide information about the oxygen status of patients in the moderately hyperoxic range (100 mmHg< PaO2 ≤ 200 mmHg).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Preoxygenation Methods | Effects of Different Preoxygenation Methods on SaO2, FiO2 and FeO2 with Oxygen Reserve Index | During the surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oxygen Reserve Index, Preoxygenation, General Anesthesia, Cesarean Section